Cytomegalovirus Disease Clinical Trial
Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.
This is a Phase 2, randomized, double-blind, placebo-controlled study of NPC-21 for kidney transplant recipients at high risk of CMV infection in the United States and Japan. Approximately 108 eligible patients will be randomized prior to first study drug administration to receive low-dose NPC 21, high-dose NPC-21, or placebo. Randomization will be stratified by region (United States or Japan) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02439957 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
|
Phase 3 | |
| Terminated |
NCT02439970 -
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04904614 -
Letermovir Use in Heart Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01509404 -
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
|
Phase 4 | |
| Completed |
NCT01573039 -
Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant Recipients
|
N/A | |
| Completed |
NCT00907686 -
TT-CMV Observational Birth Cohort Study
|
N/A | |
| Completed |
NCT04129398 -
MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
|
Phase 3 | |
| Recruiting |
NCT00828503 -
Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
|
Phase 2 |